Migraine. Migraine
Conditions
Interventions
Intervention 1: Intervention group: For 8 weeks, daily intake of one tablet containing 100 mg of first-class Sargol saffron (preparation of tablets will be done at the Faculty of Pharmacy). Interventi
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients who are willing to participate in the study Migraine Migraine diagnosis by a neurologist based on the International Classification of Headache Disorders-3 (ICHD-3) Age 20 to 50 years At least one year has passed since the migraine diagnosis
Exclusion criteria
Exclusion criteria: Patients with a history of saffron allergy Suffering from cardiovascular diseases, diabetes, liver and kidney diseases, malignancies and other neurological disorders Pregnancy and lactation Taking anticoagulants Adherence to a specific diet in the last 3 months Smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of migraine attacks. Timepoint: At baseline and after 8 weeks. Method of measurement: Visual Analogue Scale (VAS).;Migraine frequency. Timepoint: At baseline and after 8 weeks. Method of measurement: Question / Number of attacks per month.;Duration of migraine headache. Timepoint: At baseline and after 8 weeks. Method of measurement: Question/ average duration of migraine attacks per headache (hours).;Serum levels of C-reactive protein (CRP). Timepoint: At baseline and after 8 weeks. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of superoxide dismutase (SOD). Timepoint: At baseline and after 8 weeks. Method of measurement: Kiazist biochemical kit.;Serum level of malondialdehyde (MDA). Timepoint: At baseline and after 8 weeks. Method of measurement: Kiazist biochemical kit.;Total antioxidant capacity. Timepoint: At baseline and after 8 weeks. Method of measurement: Kiazist biochemical kit.;Serum level of Nitric Oxide. Timepoint: At baseline and after 8 weeks. Method of measurement: Kiazist biochemical kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mental health (Stress, anxiety, depression). Timepoint: At baseline and after 8 weeks. Method of measurement: Depression, Anxiety and Stress Scale-21 questionnaire (DASS-21).;Quality of Life of Migraine Patients. Timepoint: At baseline and after 8 weeks. Method of measurement: Migraine –Specific Quality of Life (MSQ) questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Gholamreza Askari
Esfahan University of Medical Sciences
Outcome results
None listed